Apilimod mesylate by OrphAI Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval

Apilimod mesylate is under clinical development by OrphAI Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.

Mapping the heart’s cellular blueprint: New insights into cardiac structure and disease repair

Researchers unveil the complex cellular architecture of the heart using advanced RNA sequencing and imaging techniques, shedding light on the intricate organization of heart cells

March 15, 2024

Dendritic cells found to kill CD47-deficient T cells

Researchers at Kobe University discovered an entirely new and unexpected mechanism by which the immune system can get rid of cells lacking molecules that identify

August 8, 2023

Merck KGaA’s life science unit is still feeling the Covid demand decline

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.